McGuigan Christopher, Balzarini Jan
Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK.
J Antimicrob Chemother. 2009 Oct;64(4):671-3. doi: 10.1093/jac/dkp294. Epub 2009 Aug 13.
FV100 is a promising new agent with extreme potency and specificity for varicella-zoster virus (VZV). It is the valyl ester pro-drug of Cf1743, the lead clinical candidate among the highly lipophilic bicyclic nucleoside analogue (BCNA) family discovered in Cardiff/Leuven. Cf1743 is unique amongst antivirals in terms of its structure and lipophilicity. It is exquisitely potent and selective for human VZV. FV100 has recently entered a randomized, controlled Phase II clinical trial for the treatment of shingles, sponsored by Inhibitex.
FV100是一种有前景的新型药物，对水痘带状疱疹病毒（VZV）具有极高的效力和特异性。它是Cf1743的缬氨酰酯前药，Cf1743是在卡迪夫/鲁汶发现的高度亲脂性双环核苷类似物（BCNA）家族中领先的临床候选药物。Cf1743在抗病毒药物中，其结构和亲脂性都很独特。它对人类VZV具有极强的效力和选择性。FV100最近已进入由Inhibitex赞助的用于治疗带状疱疹的随机对照II期临床试验。
